Inside Forbion’s M&A-First Playbook for Building Europe’s Biotech Winners

Description

“If a company isn’t IPO-ready, it better be M&A-ready,” says Nanna Luneborg of Forbion. She and co-founder Sander Slootweg sit down with Bloomberg Intelligence analyst Sam Fazeli to explain Forbion’s blueprint for success in Europe’s maturing biotech ecosystem. From incubating CNS-focused gene therapy startups to executing more than €100 million in financing rounds, Forbion’s thesis is rooted in scientific rigor and commercially sound exits. They also share how Europe’s capital scarcity offers hidden advantages — and why late-stage buyers still pay up for must-have innovation.